Additional file 1 of Correlations between genetically predicted lipid-lowering drug targets and inflammatory bowel disease

Additional file 1: Table S1. Phenotype descriptions and distributions. Table S2A. Characteristics of lipid-lowering genetics variants in target genes from UK Biobank database. Table S2B. Characteristics of lipid-lowering genetics variants in target genes from Willer et al. Table S3. Statistical power estimates for drug-target MR analyses. Table S4. Heterogeneity and pleiotropy tests of instrument effects (drug targets from UK Biobank database). Table S5. External validation of the causal relationship between lipid-lowering drug genetic variants and IBD IVW-MR analysis in different datasets combinations. Table S6. Heterogeneity and pleiotropy tests of instrument effects for external validation. Table S7. Association of genetically proxied inflammmatory bowel diseases with risk of lipids traits. Table S8. Causal effects and heterogeneity and pleiotropy tests of genetically predicted gut microbiota on inflammatory bowel diseases. Table S9. The relationship between genetic mimicry of lipid-lowering drugs that can affect Inflammatory bowel disease and the microbiota that can affect Inflammatory bowel disease.